COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR
SHANGHAI, CHINA - Media OutReach - 20 January 2023 - On January 20, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) announced that COMIRNATY® Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as COMIRNATY® Bivalent COVID-19 Vaccine) is officially approved as a regular imported vaccine by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of the People's Republic of China ("Macao SAR").